ARTICLE | Clinical News
OBE001: Phase II started
July 13, 2015 7:00 AM UTC
ObsEva began the double-blind, placebo-controlled, European Phase II TERM trial to evaluate oral OBE001 once daily for up to 7 days in 100 patients. ObsEva has exclusive, worldwide rights to OBE001 fr...